BIEL: The Billion-Dollar Long Game
Berkshire Hathaway didn’t get rich overnight—it played the long game. Now BIEL can execute that same strategy with surgical precision.
With FDA-cleared PEMF wearables like ActiPatch and RecoveryRx, BIEL is scaling AI-powered pain therapy across consumer, clinical, and veterinary markets. Paired with Viant Medical and VLMS Healthcare, it’s not a startup—it’s a synchronized machine:
Long Game Mechanics: Berkshire Style
Like Berkshire’s patient Apple play, BIEL is positioned for compounding returns—not quick flips.
Phase 1: Pay off loans
Phase 2: Stock buyback to reduce float and drive scarcity
Phase 3: PPS explosion
With only ~10B float and ~15B locked long-term, even modest demand drives major price action. Once buybacks kick in, PPS can easily surpass $1—dwarfing ROI seen in Apple, Amazon, and Bitcoin.
The ROI Math Is Wild
$0.0003/share → $0.01 → $0.04 → $0.10 → $1
$300K investment → $1B potential and with $40M in tax-loss carryforwards much of that upside stays untaxed.
Netflix Economics Meets Health
ActiPatch: ~$35/month for 720 hours (1 month) of relief = same price as Netflix Broader audience: chronic pain + pet wellness
Higher margins: scalable software, no studios and overpaid actors
Federal tailwind: NOPAIN Act drives VA reimbursement
BIEL’s multi-channel, subscription-based model mimics early Netflix—only healthier.
They’re Not Just Betting on BIEL
Viant and VLMS aren’t outside investors—they’re fueling the engine from inside. Device manufacturing, AI marketing (smart phone app), hospital contracts—this alliance is BIEL.
This isn’t hype. It’s the blueprint for a public-market breakout driven by execution, virality, and equity ownership.
#LongGame #MicrocapMoonshot #SmartRelief #AIHealthcare #Viant #VLMS #BIEL
Berkshire Hathaway didn’t get rich overnight—it played the long game. Now BIEL can execute that same strategy with surgical precision.
With FDA-cleared PEMF wearables like ActiPatch and RecoveryRx, BIEL is scaling AI-powered pain therapy across consumer, clinical, and veterinary markets. Paired with Viant Medical and VLMS Healthcare, it’s not a startup—it’s a synchronized machine:
Long Game Mechanics: Berkshire Style
Like Berkshire’s patient Apple play, BIEL is positioned for compounding returns—not quick flips.
Phase 1: Pay off loans
Phase 2: Stock buyback to reduce float and drive scarcity
Phase 3: PPS explosion
With only ~10B float and ~15B locked long-term, even modest demand drives major price action. Once buybacks kick in, PPS can easily surpass $1—dwarfing ROI seen in Apple, Amazon, and Bitcoin.
The ROI Math Is Wild
$0.0003/share → $0.01 → $0.04 → $0.10 → $1
$300K investment → $1B potential and with $40M in tax-loss carryforwards much of that upside stays untaxed.
Netflix Economics Meets Health
ActiPatch: ~$35/month for 720 hours (1 month) of relief = same price as Netflix Broader audience: chronic pain + pet wellness
Higher margins: scalable software, no studios and overpaid actors
Federal tailwind: NOPAIN Act drives VA reimbursement
BIEL’s multi-channel, subscription-based model mimics early Netflix—only healthier.
They’re Not Just Betting on BIEL
Viant and VLMS aren’t outside investors—they’re fueling the engine from inside. Device manufacturing, AI marketing (smart phone app), hospital contracts—this alliance is BIEL.
This isn’t hype. It’s the blueprint for a public-market breakout driven by execution, virality, and equity ownership.
#LongGame #MicrocapMoonshot #SmartRelief #AIHealthcare #Viant #VLMS #BIEL
1
